Deal of the Day — limited-time pharmacy picks!
Nintena 150mg Capsule

Nintena 150mg Capsule

Prescription requiredRx Required

Salt Composition: Nintedanib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

10 Capsule(s) In A Strip

About The Product

Non-small cell Lung Cancer

Nintena 150mg capsule contains Nintedanib as an active ingredient. It prescribes to treat idiopathic pulmonary fibrosis in adults and non-small cell lung cancer. It work by inhibiting the pathways that promote uncontrolled multiplication of cancer cells and control disease progression. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

Uses

  • Idiopathic pulmonary fibrosis
  • Non-small cell lung cancer​

Side Effects

Most side effects of Nintena 150mg capsule do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

  • Abdominal pain
  • Diarrhea
  • Nausea
  • Vomiting
  • Abnormal liver function tests
  • Loss of appetite
  • Headache
  • Weight loss
  • High blood pressure

How To Use

  • Doctor determines the exact dose and duration with Nintena 150mg capsule as per the overall health condition of the patient.
  • The typical recommended dose of the capsule is twice daily.
  • This capsule should be taken with food, but at the fix time every day to get effective results.
  • Don't miss a dose or overdose on the medicine.
  • Swallow it as a whole with a glass of water and do not crush, chew, or open it.

How It Works

  • Nintena 150mg capsule is an anticancer medicine that contains nintedanib.
  • This medicine works by inhibiting the pathways responsible for fibrosis and reducing the scarring & swelling in the lungs results in better breath.
  • It also blocks the action of abnormal protein to stop or slow the spread of cancer cells.

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Nintena 150mg, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Pregnancy
Do not take Nintena 150mg without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breast Feeding
Breastfeeding women should discuss the potential risks and benefits of the Nintena 150mg capsule with their healthcare provider before starting treatment.
Driving
Nintena 150mg capsule may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Kidney
Share your medical history with the doctor before starting the Nintena 150mg capsule. Do not take it without consulting a doctor if you have any kidney related issue.
Liver
Share your medical history with the doctor before starting the Nintena 150mg. Do not take it without consulting a doctor if you have any liver related issue.

FAQs

Nintena 150mg works by inhibiting the pathways responsible for fibrosis and reducing the scarring & swelling in the lungs results in better breath.

It also blocks the action of abnormal protein to stop or slow the spread of cancer cells.

References

  • Reck, M., & Mellemgaard, A. (2015). Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib. Biologics: Targets and Therapy, 47-56.
  • McCormack, P. L. (2015). Nintedanib: first global approval. Drugs, 75(1), 129-139.
  • Rashdan, S., & Hanna, N. (2014). Nintedanib for the treatment of non-small-cell lung cancer. Expert opinion on pharmacotherapy, 15(5), 729-739.
  • Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015). Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 45(5), 1434-1445.
  • Varone, F., Sgalla, G., Iovene, B., Bruni, T., & Richeldi, L. (2018). Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert opinion on pharmacotherapy, 19(2), 167-175.
  • Caglevic, C., Grassi, M., Raez, L., Listi, A., Giallombardo, M., Bustamante, E., ... & Rolfo, C. (2015). Nintedanib in non-small cell lung cancer: from preclinical to approval. Therapeutic advances in respiratory disease, 9(4), 164-172.​

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026